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Background
Over the last decade, we have shown that cGMP, derived
from bradykinin, nitric oxide (NO•, both from endog-
enous and exogenous sources) or natriuretic peptides, is a
potent inhibitor of cardiac hypertrophy, across isolated
cardiomyocytes and intact hearts both ex vivo and in vivo.
However, NO￿ bioavailability is reduced due to scaveng-
ing by ROS; furthermore, oxidation of sGC may result in
sGC dysfunction (including loss of responsiveness to
NO￿). In the present study, we tested the hypothesis that
the NO￿-independent sGC stimulator BAY 41-2272 and
the NO-independent sGC activator BAY 58-2667 elicit
powerful antihypertrophic actions.
Materials and methods
Neonatal rat cardiomyocytes were incubated at 37°C in
the presence of the hypertrophic stimulus, endothelin-1
(ET1, 60 nM) ± BAY 41-2272 or BAY 58-2667 (0.01–0.3
μM) for 48 h in serum-free conditions. Cardiomyocyte
hypertrophy was assessed in live cells using conventional
in vitro markers of hypertrophy, two dimensional area and
cardiomyocyte  de novo protein synthesis. Results were
expressed as % paired control cardiomyocytes, mean ± SE.
Results
See Table 1.
Conclusion
These results provide evidence that BAY 41-2272 and BAY
58-2667 elicit concentration-dependent inhibition of car-
diac hypertrophy in vitro, in the absence of confounding
haemodynamic factors and even at low (submicromolar)
concentrations. These novel NO￿-independent sGC lig-
ands thus potentially may serve as useful antihypertrophic
agents in patients, independent of blood pressure.
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Table 1: sGC ligands inhibit cardiomyocyte hypertrophy
Control ET1 alone ET1 + BAY (0.01 μM) ET1 + BAY (0.03 μM) ET1 + BAY (0.10 μM) ET1 + BAY (0.30 μM)
Cell size (% paired control cardiomyocytes, both n = 4)
BAY 41-2272 100 ± 0% 146 ± 9%* 128 ± 5%# 116 ± 7%# 106 ± 6%# 108 ± 6%#
BAY 58-2667 100 ± 0% 141 ± 8%* 133 ± 11% 123 ± 7%# 113 ± 2%# 108 ± 12%
De novo protein synthesis (% paired control cardiomyocytes, n = 5–6)
BAY 41-2272 100 ± 0% 122 ± 1%* 102 ± 1%# 101 ± 1%# 102 ± 2%# 110 ± 0%#
BAY 58-2667 100 ± 0% 135 ± 2%* 110 ± 3% 117 ± 3% 107 ± 2%# 108 ± 3%
*p < 0.05 versus control; #p < 0.05 versus ET1, on one-way RM. DMSO, the vehicle for the sGC ligands, had no effect on either parameter either 
alone, or in the presence of ET1.